Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
暂无分享,去创建一个
L. Gordon | J. Winter | B. Pro | X. Mi | J. Kaplan | R. Karmali | Frédérique St-Pierre | Shuo Ma | Kelly D Foster | F. St-Pierre